Targeted drug achieves 43% response rate in KRAS-mutated lung cancer: Experimental drug adagrasib also shows activity in lung cancer metastases to the brain
Nearly 43% of patients with non-small cell lung cancer (NSCLC) whose lung cancers harbored a specific KRAS mutation responded to the experimental drug adagrasib, and the targeted agent also showed activity against lesions in the brain that metastasized from the lung tumors, according to results of a study led by Dana-Farber Cancer Institute investigators. Mutations […]
High fat diet, unregulated athletic exercise endurance enhancers linked to risk of pancreatic cancer
Researchers at the University of Michigan Rogel Cancer Center have found a cell nuclear receptor activated by high fat diets and synthetic substances in unregulated athletic performance enhancers fuels the progression of precancerous pancreas lesions into pancreatic cancer. Pancreatic ductal adenocarcinoma is a highly lethal form of cancer with rising occurrence, and strategies to prevent […]
Check Troponin in RCC Patients Before Checkpoint-VEGFR Inhibitor Combo
Advanced renal cell carcinoma (RCC) patients with high serum levels of troponin T had a greater risk of serious cardiac events when treated with an immune checkpoint inhibitor and VEGFR inhibitor combination, data from the phase III JAVELIN Renal 101 trial indicated. For patients assigned to the avelumab (Bavencio) plus axitinib (Inlyta) arm, 17.1% of […]
When it comes to obesity, the problem isn’t an excess of fat but its loss of function, researchers argue
Cell Press. “When it comes to obesity, the problem isn’t an excess of fat but its loss of function, researchers argue.” ScienceDaily. ScienceDaily, 3 February 2022. <www.sciencedaily.com/releases/2022/02/220203122923.htm>. Cell Press. (2022, February 3). When it comes to obesity, the problem isn’t an excess of fat but its loss of function, researchers argue. ScienceDaily. Retrieved February 4, […]
Stem cell discoveries hold potential to improve cancer treatment: Findings could lead to new ways to fight disease and help patients recover faster
Two recent discoveries by stem cell scientists at Cedars-Sinai may help make cancer treatment more efficient and shorten the time it takes for people to recover from radiation and chemotherapy. In the first study, published in the journal Blood, investigators discovered a protein that is expressed by blood stem cells that could aid in identifying, […]
Lymphoma cell metabolism may provide new cancer target
Aggressive and relatively common lymphomas called diffuse large B cell lymphomas (DLBCLs) have a critical metabolic vulnerability that can be exploited to trick these cancers into starving themselves, according to a study from researchers at Weill Cornell Medicine and Cornell’s Ithaca campus. The researchers, whose study was published Dec. 13 in Blood Cancer Discovery, showed […]
High-resolution lab experiments show how cells ‘eat’: Study solves a 40-year-old problem in cell biology
A new study shows how cell membranes curve to create the “mouths” that allow the cells to consume things that surround them. “Just like our eating habits basically shape anything in our body, the way cells ‘eat’ matters for the health of the cells,” said Comert Kural, associate professor of physics at The Ohio State […]
How moles change into melanoma
Moles and melanomas are both skin tumors that come from the same cell called melanocytes. The difference is that moles are usually harmless, while melanomas are cancerous and often deadly without treatment. In a study published today in eLife Magazine, Robert Judson-Torres, PhD, Huntsman Cancer Institute (HCI) researcher and University of Utah (U of U) […]
FDA OKs PD-1 Inhibitor for Adjuvant Treatment of Kidney Cancer
The FDA approved pembrolizumab (Keytruda) for the adjuvant treatment of renal cell carcinoma (RCC) for patients who have an intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions, the agency announced. Approval was based on results from the KEYNOTE-564 trial, which demonstrated that adjuvant pembrolizumab following nephrectomy significantly […]
Immunotherapy Combo in Advanced RCC Led to More Time Off Treatment
Nearly one-fifth of patients with intermediate- or poor-risk advanced renal cell carcinoma (RCC) treated with nivolumab (Opdivo) plus ipilimumab (Yervoy) in the CheckMate 214 trial were alive and treatment free beyond 3 years. Among the phase III trial participants, the treatment-free survival (TFS) rate at 42 months was 18% for those who were randomized to […]